P/B
0,5
Aclarion
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
$8.5M
Market Cap • 9/23/2026
2015
(11 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
101,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
11,5
EPS
—
Market Cap
Market Cap
8,5M
EV
-7,8M
EV/Revenue
-93,2
EV/EBITDA
0,8
EV/EBIT
0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-151,8%
Total Yield
-151,8%
Payout
0%
Retained Earnings
-64,1M
Profitability
Gross Margin
21,8%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
1405,8%
Capex/Revenue
27,3%
Capex/D&A
9,4%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
0,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
3,7%
CAGR Op. Income 5Y
20,2%
CAGR Net Income 5Y
18,9%
CAGR OCF 5Y
19,1%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
16,2
Quick Ratio
15,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!